Beijing Kexing Biological Products Co., Ltd. is a biotechnology high-tech enterprise jointly funded by Kexing Holdings (Hong Kong) Co., Ltd. and Beijing Peking University Weiming Biological Engineering Group Co., Ltd. The company is registered in Peking University Biological City, Zhongguancun High-tech Park, Beijing, 200 1. The purpose of the company's establishment and operation: in line with the desire to develop China's bioengineering high-tech industry, we will adopt advanced scientific and technological achievements at home and abroad and introduce international scientific management methods to conduct research, production and sales of human vaccines and related products, and provide technical consultation and technical services to improve the prevention and treatment level of various major diseases at home and abroad, including hepatitis A and hepatitis B, and make contributions to human health.
Beijing Kexing Holdings Co., Ltd. is the first vaccine company listed in the United States in China, and holds 765,438+0.6% shares of Beijing Kexing Biological Products Co., Ltd. through its Hong Kong branch. Beijing Kexing Holding Company also has a wholly-owned subsidiary in Tangshan, Hebei Province-Tangshan Yi 'an Bioengineering Co., Ltd., which is dedicated to the research and development of veterinary vaccines. On June 4, 2009, 165438+ Beijing Kexing Holdings Co., Ltd. announced that it had successfully switched to the Nasdaq global market. It is expected that 165438+ 10 will be officially listed and traded on the Nasdaq Stock Exchange with the trading code of SVA. Previously, Beijing Kexing Holding Company was listed on the American Stock Exchange (AMEX).
Beijing Branch has established a professional R&D and management system, and formed an R&D model with enterprises as the main body and Industry-University-Research as the combination. We have successful experience and technical team in the research and development of new vaccines, insist on independent innovation to build core competitiveness, adopt advanced technology to continuously develop new vaccines and carry out technical transformation on traditional vaccines. Beijing Kexing's R&D has been strongly supported by the government and has carried out extensive cooperation with famous universities and research institutes at home and abroad. Beijing Kexing has successively undertaken more than 20 national high-tech R&D projects (863 Plan) such as "Development of Inactivated SARS Vaccine" and "Broad-spectrum Influenza Epidemic Vaccine", national key scientific and technological research projects such as "Avian Influenza Vaccine for Human Use", national major scientific and technological projects, national high-tech industrialization demonstration projects, national high-tech industrialization projects and major projects in Beijing, and successfully realized the industrialization of many scientific and technological achievements. When people expect to control diseases with vaccines, Beijing Kexing has taken the lead.